Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
<!-- Name:DistributionId Value:8788531 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Beam Therapeutics
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
<!-- Name:DistributionId Value:8777528 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on…
CAMBRIDGE, Mass., Dec. 10, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today…
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today…
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational…
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today…
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base…
CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today…
Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today…
Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today…
Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT…
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today…
Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle…
CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today…